You are here


Last reviewed by: Aleksey Portnov , medical expert, on 01.06.2018

Gold preparations, which include Tauredon, are used to alleviate the condition of patients with rheumatoid arthritis.

Indications of the tauredona

For more than 80 years, Tauredon has been used to improve the condition of patients with rheumatoid arthritis, including juvenile rheumatoid arthritis, as well as psoriatic arthritis.

Release form

Gold drug Tauredon is produced in the form of an injection solution - it is a yellowish transparent drug liquid, the active ingredient of which is sodium aurotiomalate. The solution is packaged in glass ampoules of 0.5 ml each. The cell transparent plate contains five ampoules of Tauredon. A box of cardboard contains two cell plates.

One ampoule can be represented by a different dosage of the drug:

  • Tauredon® 10: The ampoule contains 10 mg of the active ingredient (this corresponds to 4.53 mg of gold).
  • Touredon® 20: The ampoule contains 20 mg of the active ingredient (this amount corresponds to 9.06 mg of gold).
  • Tauredon® 50: The ampoule contains 50 mg of the active ingredient (this corresponds to 22.65 mg of gold).

In the role of an auxiliary component is injected water.


Medication based on the gold compound has the properties of inhibiting the production of antibodies in lymphocytic and plasma cells. Tauredon is considered the main drug in the therapeutic regimens used in autoimmune diseases.

Tauredon provokes inhibition of antigeninduced activation of lymphocytic cells, inhibits phagocytosis of monocytes and granulocytes, normalizes the membranes of lysosomes, strengthens collagen fibers with filling of immunoactive zones, which can give impetus to the development of an autoimmune process.

Tauredon should be taken for a long time: the first signs of improvement can be observed only after 9-17 weeks of treatment, with a general course of 300-800 mg of gold.


Limit concentration of tauredon in serum is detected 3-6 hours after administration. Increased gold content is observed in the layers of the tissues of the reticuloendothelial system.

Relatively large content of the drug is recorded in the adrenal gland and in the cortical layer of the renal parenchyma. A small amount of gold is noted in the muscle and bone tissue.

Tauredon almost completely forms a connection with plasma proteins. After a day in the blood, about 75% of the level is detected, which was recorded six hours after the injection.

On the average, 83-90% of the active ingredient is excreted from the body through the urinary system, and only up to 17% - with the calves.

If the weekly amount of Tauredon is 50 mg, then the concentration equilibrium of gold comes after 6 weeks. If two injections of 25 mg are administered weekly to the patient, the serum gold level before the next injection can be about 3.5 μg per ml.

The half-life of Tauredon can be about 27 days.

Use of the tauredona during pregnancy

Pregnancy and the lactation period are contraindications for the treatment of the drug Tauredon.


  • Violations of blood-forming processes.
  • Renal dysfunction and severe liver disease.
  • Pulmonary tuberculosis in the active phase.
  • Common connective tissue pathologies (collagenoses).
  • Propensity to allergic reactions, hypersensitivity to compounds of heavy metals and gold.
  • Ulcerative enterocolitis and colitis.
  • Diabetes mellitus with complications.
  • Periods of pregnancy and lactation.

Side effects of the tauredona

Approximately 30% of patients treated with Tauredon are accompanied by side effects. Such effects can be:

  • dermatitis, ulcers in the oral cavity;
  • protein in the urine;
  • itching of the skin;
  • anemia, leukopenia, thrombocytopenia;
  • congestion of bile, impaired hepatic function, pancreatitis;
  • increased hair loss, increased reaction to the action of ultraviolet rays.

At the very beginning of treatment, such transitory symptoms as rapid heartbeat, skin rashes, headaches, fever, lowering of blood pressure, epigastric pain may be observed.

If the side effects are pronounced, the doctor may reconsider the appointment and cancel the Tauredon.

Dosing and administration

Injectable injection Tauredon is carried deep into the gluteus muscle. Other methods of drug administration are not practiced.

The contents of the ampoule can not be heated.

Standard dosage Tauredon does not exist: the amount of the drug is selected strictly individually.

Given the kinetic data, treatment with Tauredon begins with a trial injection - to assess the tolerability of the drug, for the correct choice of dosage. Next, the doctor determines the maintenance dose of Tauredon, which could provide a stable content of gold in the circulatory system and tissues.

Most often at the first stage, the doctor appoints two Tauredon injections per week, according to this pattern:

  • I-III injection involves the administration of 10 mg of medication (Tauredon 10);
  • IV-VI injection involves the administration of 20 mg of medication (Taudedon 20);
  • with VII injections of 50 mg of medication (tauredon 50) twice weekly, or 100 mg once a week (two doses of tauredon 50).

Such a quantity of the drug should be preserved until a visible effect is obtained, while the total amount of 1600 mg should not be exceeded. If the total amount has already been reached, and clinical relief has not come, then further treatment with Tauredon is considered impractical.

If clinical improvement is evident, further maintenance treatment is prescribed using a monthly amount of the drug 100 mg, or 50 mg once every two weeks. Such therapy can be continued for several months and even years, at the discretion of the doctor.

In pediatrics, Tauredon is administered before the onset of the saturation phase of 0.7-1 mg per kg of child weight per week. With a supportive treatment option, use a dosage of 1 mg per kg of body weight 1-2 times per month.

Introduction Tauredon children are discontinued if the clinical effect of treatment does not occur within 6-9 months.


Overdose Tauredon is noted relatively often, even under normal treatment regimens. In most cases, signs of overdose are more pronounced side effects.

If the patient has anaplastic anemia, agranulocytosis and thrombocytopenia during an injection of Tauredon, or an enterocolitis develops, then blood transfusion with further glucocorticosteroid treatment may be prescribed. To accelerate the excretion of gold from the circulatory system and tissues, dimercaprol or H-acetylcysteine is prescribed.

If the patient develops a vasomotor reaction with a sharp drop in blood pressure, then urgent anti-shock therapy is required.

Interactions with other drugs

Tauredon injections often cause multiple side effects. In order not to increase the frequency of these manifestations, do not combine the administration of the drug with certain other substances:

  • phenylbutazone;
  • cytostatic drugs;
  • metamizole;
  • photosensitizing agents.

Tauredon can worsen the therapeutic effect of D-penicilamine.

Storage conditions

Preserve Tauredon in a darkened room with a temperature range of +15 to + 25 ° C. The medication should not be in the children's sight.

Shelf life

Tauredon may be stored for up to 3 years from the date of manufacture.

Found an error? Select it and press Ctrl + Enter.


To simplify the perception of information, this instruction for use of the drug "Taureledon" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.